Jagsonpal Pharmaceuticals Limited has made the audio recording of its Q1 FY27 earnings conference call available to investors and stakeholders on its official website. The recording, which discusses the company's financial performance for the quarter ended September 30, 2026, is accessible via the investor relations section of the Jagsonpal Pharmaceuticals Limited website. The earnings call was conducted on July 30, 2026, at 2:30 P.M., providing a platform for management to address queries regarding the Q1 FY27 results.

The disclosure of the audio recording is in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed entities to make such recordings available to ensure transparency and equal access to information for all shareholders. The company had previously issued an intimation on July 22, 2026, regarding the schedule of the earnings call and the subsequent availability of the recording.

Key Details of the Earnings Call

The following table outlines the essential details of the earnings conference call:

Investors can access the recording by visiting the dedicated earnings calls page on the Jagsonpal Pharmaceuticals Limited website. The link provided in the exchange filing directs users to https://www.jagsonpal.com/investor-relations/earning-calls/ , where the audio file is hosted alongside other investor communications.

Regulatory Compliance and Filing

The announcement was formally communicated to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE). The filing was signed by Pratham Rawal, who serves as the Company Secretary and Compliance Officer for Jagsonpal Pharmaceuticals Limited. The digital signature on the document confirms the authenticity of the disclosure, with a timestamp of July 30, 2026, at 17:13:45 +05'30'.

This procedural step ensures that all market participants have access to the detailed discussions held during the earnings call, which may include insights into operational performance, strategic initiatives, and future outlook beyond the numerical data presented in the financial results. The availability of the recording supports the regulatory framework's emphasis on transparency and informed decision-making by investors.

Jagsonpal Pharmaceuticals reported a 22.2% year-on-year increase in standalone net profit to ₹131.89 million for the quarter ended June 30, 2026 (Q1FY27), driven by an 8.8% rise in revenue from operations to ₹822.32 million. Operating EBITDA grew 21.4% to ₹191 million, expanding the margin to 23.2% from 20.8% in the prior year period. This performance significantly outpaced the Indian pharmaceutical market’s average growth of 11.6%, allowing Jagsonpal to improve its industry rank to #88. The results reflect strong operating leverage, as total expenses grew only 5.4% year-on-year despite the revenue surge.

The Board of Directors approved these unaudited financial results on July 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Walker Chandiok & Co LLP served as the statutory auditor, issuing a limited review report on the financial statements. Management highlighted that disciplined capital allocation, including a concluded ₹400 million share buyback and the acquisition of Aequitas Healthcare, did not compromise liquidity, leaving cash reserves robust at ₹1,700 million.

Financial Highlights

The table below summarizes key financial metrics for Q1FY27 compared to Q1FY26 and Q4FY26.

*Operating EBITDA and margins are calculated before Employee Stock Option Plan (ESOP) costs.

Gross profit rose to ₹536 million from ₹487 million in Q1FY26, with gross margin expanding to 65.2% from 64.4%. Total expenses were recorded at ₹632 million, up 17.7% quarter-on-quarter but demonstrating significant year-on-year efficiency as expense growth lagged revenue growth. Other income remained flat at ₹28 million, while finance costs were negligible at ₹3 million.

Brand Performance and Market Position

Jagsonpal’s top 10 brands contributed approximately 58% of total revenue, with nine of these brands ranked in the top five within their respective molecule categories. Key growth drivers included Maintane Inj., which saw a 43% year-on-year growth in moving average sales (MAT) to ₹34 million, and Maintane Tab, which grew 55% to ₹13 million. Indocap, the top-ranked brand, maintained steady growth at 4% to ₹41 million MAT. Lycored grew 16% to ₹21 million, while Endoreg expanded 24% to ₹10 million. The company holds a strong niche position, ranking #8 in the Corporate CVM segment according to CMARC RPM data, with deep penetration in Gynecology, Orthopedics, Pediatrics, and Dermatology.

Strategic Developments: Aequitas Acquisition

During the quarter, Jagsonpal completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited for ₹208 million, funded through internal accruals. Aequitas, a specialty-focused pharmaceutical company established seven years ago, reported FY26 revenue of ₹533 million. The acquisition provides Jagsonpal with immediate access to over 1,000 hospitals and relationships with more than 4,000 doctors, a network that would take four to six years to build organically.

Management outlined a value creation roadmap targeting approximately ₹100 million in EBITDA by Year 2 post-integration. Key initiatives include cross-selling Jagsonpal’s portfolio across Aequitas’s hospital channels, entering institutional tenders, and consolidating supply chains to eliminate duplicate overheads. The integration has already begun, with the launch of Ventrixa (Aztreonam + Avibactam) and the alignment of governance structures. Aequitas remains debt-free, ensuring no additional leverage on Jagsonpal’s balance sheet.

What the Numbers Show

The divergence between revenue growth (8.8%) and total expense growth (5.4%) underscores improved operating leverage for Jagsonpal Pharmaceuticals in Q1FY27. The expansion of Operating EBITDA margin to 23.2% from 20.8% indicates strengthening core profitability, driven by enhanced medical representative productivity and higher sales across key brands. Furthermore, the company’s ability to maintain a ₹1,700 million cash balance despite deploying ₹400 million for buybacks and ₹208 million for acquisitions highlights the strength of its asset-light business model. With free cash flow conversion reaching 92% in FY26 and net working capital days reduced to 11 from 59 in FY22, Jagsonpal demonstrates exceptional capital efficiency, positioning it well for sustained organic growth and further value-accretive inorganic opportunities.